CG Results Healthcare has advised UCB on its divestment of Alprostadil products to Advanz Pharma
- Service: Divestments
- Sector: Healthcare
- Sub Sector: Pharma & Biotech
- Engagement Type: Sell Side
CG Results Healthcare is pleased to announce it was the exclusive corporate finance advisor to UCB, a global biopharmaceutical company focused on neurology and immunology, on its divestment of the rights to a portfolio of Alprostadil products in 10 European Union countries, as well as the United Kingdom, Russia, Ukraine and Brazil, to Advanz Pharma.
This transaction is testament to CG Results Healthcare’s expertise in advising companies in the healthcare and life sciences sector, which follows Duke Street’s recent acquisition of Kent Pharmaceuticals.
The alprostadil product portfolio consists of two established, niche, injectable Prostaglandin E1 formulations for the treatment of erectile disfunction and peripheral arterial occlusive disease. Alprostadil is marketed under the brand names of Prostavasin®, Viridal®, Vasaprostan® and Edex®.
These medicines are excellent strategic fits, and their integration into our global commercial infrastructure is proceeding as anticipated.
CEO of Advanz Pharma